
BMEA Stock Forecast & Price Target
BMEA Analyst Ratings
Bulls say
Biomea Fusion Inc. demonstrates a strong positive outlook due to its innovative pipeline of oral covalent small-molecule drugs, particularly icovamenib, which has shown durable glycemic control and significant reductions in HbA1c in early clinical trials. Furthermore, the company’s progress with BMF-650, exhibiting promising preclinical weight reduction and glucose-lowering effects, coupled with its favorable safety data from chronic toxicology studies, reinforces the potential for these candidates in treating diabetes and obesity. Lastly, the financials indicate a notable improvement, with a reduced net loss of $16.4 million for Q3 2025 compared to $32.8 million in Q3 2024, alongside a decrease in operating expenses by over 50% year-over-year, highlighting enhanced financial efficiency.
Bears say
Biomea Fusion Inc. reported a significant reduction in Research and Development (R&D) expenses, dropping from $27.2 million in Q3 2024 to $14.4 million in Q3 2025, alongside a decrease in General and Administrative (G&A) expenses from $6.8 million to $4.2 million. This reduction in expenses raises concerns about the company's ability to effectively advance its clinical programs and maintain growth in research output, potentially indicating financial constraints. Furthermore, the adjustment of the price target from $16.00 to $12.00 reflects a reassessment of the company's financial outlook, exacerbating the negative sentiment surrounding its stock.
This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.
BMEA Analyst Forecast & Price Prediction
Start investing in BMEA
Order type
Buy in
Order amount
Est. shares
0 shares